



ORYZON

Pioneering Personalized Medicine in
EPIGENETICS

CORPORATE PRESENTATION
July 2020

Legal Notice

DISCLAIMER This document has been prepared by Oryzon Genomics, S.A. exclusively for use during the presentation. Oryzon Genomics, S.A. does not assume liability for this document if it is used with a purpose other than the above. The information and any opinions or statements made in this document have not been verified by independent third parties; therefore, no express or implied warranty is made as to the impartiality, accuracy, completeness or correctness of the information or the opinions or statements expressed herein. Oryzon Genomics, S.A. does not assume liability of any kind, whether for negligence or any other reason, for any damage or loss arising from any use of this document or its contents. Neither this document nor any part of it constitutes a contract, nor may it be used for incorporation into or construction of any contract or agreement. Information in this document about the price at which securities issued by Oryzon Genomics, S.A. have been bought or sold in the past or about the yield on securities issued by Oryzon Genomics, S.A. cannot be relied upon as a guide to future performance.

IMPORTANT INFORMATION This document does not constitute an offer or invitation to purchase or subscribe shares, in accordance with the provisions of Law 24/1988, of 28 July, on the Securities Market, Royal Decree-Law 5/2005, of 11 March, and/or Royal Decree 1310/2005, of 4 November, and its implementing regulations. In addition, this document does not constitute an offer of purchase, sale or exchange, nor a request for an offer of purchase, sale or exchange of securities, nor a request for any vote or approval in any other jurisdiction. The shares of Oryzon Genomics, S.A. may not be offered or sold in the United States of America except pursuant to an effective registration statement under the Securities Act of 1933 or pursuant to a valid exemption from registration. Any public offering of the Company's securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company or the selling security holder, as applicable, that will contain detailed information about the Company and management, as well as financial statements.

FORWARD-LOOKING STATEMENTS This communication contains forward-looking information and statements about Oryzon Genomics, S.A., including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates" and similar expressions. Although Oryzon Genomics, S.A. believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon Genomics, S.A. shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon Genomics, S.A., that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon Genomics, S.A. to the Comisión Nacional del Mercado de Valores, which are accessible to the public. Forward-looking statements are not guarantees of future performance. They have not been reviewed by the auditors of Oryzon Genomics, S.A. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon Genomics, S.A. or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon Genomics, S.A. on the date hereof. Except as required by applicable law, Oryzon Genomics, S.A. does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Risk Factors

In addition to the existing registration document (documento de registro) filed with the Spanish National Securities Market Commission (Comisión Nacional del Mercado de Valores) (the “CNMV”) on 23 July 2019, please see an additional risk factor below

Risk Related to Public Health Emergency or Pandemic

A strain of SARS-CoV-2 coronavirus, which causes the disease known as COVID-19, originated in China, has progressively spread to other countries around the world since the end of 2019. In March 2020 the World Health Organization declared COVID-19 a global pandemic.

Given the fast spread of the coronavirus globally, many states are taking unprecedented decisions such as closing their borders to international travelers and placing restrictions on the movement of their citizens in order to contain the pandemic.

Risks related to public health emergencies or pandemics have revealed a potential risk to ORYZON clinical trials. In this sense, ORYZON currently has two drugs in clinical phases, VAFIDEMSTAT and IADADEMSTAT, in which several clinical trials are being conducted.

The protection of the patients’ health participating in clinical trials, their families and the health personnel involved, may result in a loss of data relating to visits and/or evaluations not being carried out.

Likewise, in the event of health emergencies or pandemics, situations of confinement of the population may occur in certain geographical areas, leading to delays, cancellations and early termination of clinical trials.

In addition, the impact, effects and duration of the effects of health emergencies or pandemics are highly uncertain and could affect the financial markets, limiting the Company's financing capacity and adversely affecting the equity, financial position and results of ORYZON.

The impact of the risk related to health emergencies or pandemics materializing could increase the probability of failure to enter into license agreements and, consequently, reduce the income those could generate, as illustrated by the risk of loss associated with failure to enter into license agreements.

Company Highlights

- ✓ A **clinical stage** biopharmaceutical company developing innovative therapies in the field of **Epigenetics**
- ✓ **Two molecules** that have already shown **positive data in humans**
- ✓ 2 Phase IIa trials in oncology; 4 Phase IIa trials in CNS and 1 Phase II trial in Covid-19
- ✓ Large IP portfolio with technology fully developed in-house
- ✓ A **publicly traded** company on the **Spanish Stock Exchange** (MADX: ORY)
- ✓ Integrated in the **IBEX Small Cap Index**¹

- ✓ **Raised an aggregate of approximately €105M** (in 2015-2020)
- ✓ **Cash runway** expected until **1Q2023**
- ✓ One of the most **liquid** companies in the MicroCap group on the Spanish Stock Exchange
 - ✓ 53.1 M shares outstanding. Fully diluted
 - ✓ ≈500,000 daily volume (Avg Traded Volume in 2020³)
 - ✓ More than 43M shares negotiated in 2020 / ≈4.6 months for share full turnover⁴



BOLSA DE MADRID



ORYZON GENOMICS SA
BALANCE SHEET DATA (UNAUDITED)
(Amounts in thousands US \$)²

	March 31st, 2020	March 31st, 2019
Cash and cash equivalents	32,121	32,551
Marketable securities	155	159
Total Assets	84,301	73,158
Deferred revenue	0	0
Total Stockholders' equity	65,709	49,240

- https://www.bolsamadrid.es/docs/SBolsas/InformesSB/FS-SmallCap_ESP.pdf
- Spanish GAAPs: €29.5M see <https://www.oryzon.com/es/noticias-eventos/noticias/oryzon-anuncia-sus-resultados-y-avances-en-el-primer-trimestre-de-2020>
- <https://finance.yahoo.com/quote/ORY.MC?p=ORY.MC> (as per 19.05.2020)
- <http://www.infobolsa.es/cotizacion/oryzon?noAds=1> (as per 19.05.2020)

Epigenetic Modifications: New Targets for Drug Development




Figure from Arrowsmith et al. *Nature Reviews Drug Discovery* volume 11 (2012)

- ❖ Heritable DNA modifications that do not alter the actual DNA sequence but change gene activity and expression
 - ❖ Histone modifications
 - ❖ DNA methylation
 - ❖ microRNA, etc
- ❖ Histone modifying enzymes are “writers” or “erasers” - adding or removing epigenetic marks from histone tails
- ❖ Epigenetic dysfunctions are associated with aberrant gene expression and disease
- ❖ Epigenetic drugs can restore these transcriptional imbalances

An exciting area of world class science



Lysine specific histone demethylase 1 (LSD1): an epigenetic “eraser” that removes methyl groups from histones



LSD1 expression and activity can play a role in blocking and promoting gene expression




LSD1 plays an important role in cancer, CNS, inflammatory and viral diseases



Oryzon is pioneering epigenetics in CNS and is active in oncology

INDICATION	STUDY*	RESEARCH	PRECLINICAL	PHASE I	PHASE IIA	PHASE IIB	PHASE III	Next milestone
VAFIDEMSTAT (ORY-2001) - CNS optimized LSD1 inhibitor (‡)								
Aggression in BPD	REIMAGINE / PORTICO	[RESEARCH]				BPD: PORTICO		Phase IIB to start 4Q20/1Q21
Aggression in ADHD	REIMAGINE / ENTRANCE	[RESEARCH]						
Aggression in ASD	REIMAGINE / COLONNADE	[RESEARCH]				Phelan McDermid ★★ SETD1A-SCZ ★★		
Aggression in AD	REIMAGINE-AD / GATEWAY	[RESEARCH]				Agit-Agress in AD		
Alzheimer's disease (Mild Moderate)	ETHERAL monotherapy	[RESEARCH]						
Multiple Sclerosis (RR & SP)	SATEEN monotherapy	[RESEARCH]						
IADADEMSTAT (ORY-1001) - selective LSD1 inhibitor								
AML (Elderly Unfit)	ALICE Combo w Aza	[RESEARCH]				ALICE-2 ★		Phase IIB to start 1H21
SCLC (First Line Relapsed)	CLEPSIDRA Combo w Platinum/Etoposide	[RESEARCH]				IDEAL		Phase IIB Combo with anti-PD1 to start 1H21
ORY-3001 - selective LSD1 inhibitor								
Non Oncological	Preclinical finished	[RESEARCH]						
OTHER PROGRAMS								
HDAC6/Other undisclosed		[RESEARCH]				★ Potential options to accelerated approval path		
(‡) A new Phase II in COVID-19 has been initiated recently. Trial name: ESCAPE * IN RED, NEW PHASE IIB STUDIES UNDER INITIATION, PREPARATION OR EVALUATION								



ORYZON

**VAFIDEMSTAT a Phase II Clinical Stage Compound
with a broad developability in CNS diseases**

Vafidemstat (ORY-2001): a “Neuron-fixer” ready for Phase IIb

Preclinical characterization

- Vafidemstat is a **small molecule** LSD1 inhibitor optimized for CNS. Highly potent: low nM activity.
- **Excellent pharmacology.** High **oral** bioavailability
- **Positive** results in **7 different animal models** and in *in-vitro* models
- Epigenetic **MoA** that modulates **neuroinflammation** and expression of key **plasticity neuronal genes**

PLOS ONE

OPEN ACCESS PEER-REVIEWED
RESEARCH ARTICLE

Modulation of KDM1A with vafidemstat rescues memory deficit and behavioral alterations

Tamara Maes, Cristina Mascaró, David Rötllant, Michele Matteo Pio Lufino, Angels Estiarte, Nathalie Gubourt, Fernando Cavalcanti, Christian Oriñan-Ferré, Mercè Pallàs, Roser Nadal, Antonio Armario, Isidro Ferrer, Alberto Ortega, [...] Carlos Buesa Arjol [view all]

Published: May 29, 2020 • <https://doi.org/10.1371/journal.pone.0233468>

Article	Authors	Metrics	Comments	Media Coverage	Peer Review
---------	---------	---------	----------	----------------	-------------

Abstract

Introduction
Materials and methods
Results
Discussion
Conclusions

Abstract

Transcription disequilibria are characteristic of many neurodegenerative diseases. The activity-evoked transcription of immediate early genes (IEGs), important for neuronal plasticity, memory and behavior, is altered in CNS diseases and governed by epigenetic modulation. KDM1A, a histone 3 lysine 4 demethylase that forms part of transcription regulation complexes, has been implicated in the control of IEG transcription. Here we report the development of vafidemstat (ORY-2001), a brain penetrant inhibitor of KDM1A and IIAO3. ORY-2001 efficiently inhibits brain KDM1A at doses suitable for long term treatment, and corrects memory deficit as

Clinical characterization

- **Safe** and well tolerated so far in Phase I and various Phase II studies⁽¹⁻³⁾
 - ❖ Vafidemstat has already been administered to around 250 volunteers and patients
 - ❖ Phase IIs (MS, AD, ADHD, BPD and ASD patients) with no safety signals to date
 - ❖ Longest exposure to date: 18 months
- **High BBB penetrance (CSF levels)**
- Indirect human brain target engagement established
- **Pharmacologically active** in humans


<https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0233468>

MoA: an upstream epigenetic mechanism producing a dual activity, anti-inflammatory and prosynaptic

LSD1 localizes *in-vivo* to enhancers and promoters of confirmed CNS disease risk genes

LSD1 binds to TFs that control IEG expression and stress in the PFC-amygdala axis, including SRF

- Vafidemstat **up-regulates** genes associated with **Neuroplasticity & Cognition**
- Vafidemstat **reduces** the expression of **inflammatory** genes as S100A9 and others in SAMP8 AD model and IL-6, IL-1B and many others in MS models



LSD1 inhibition rescues different phenotypes in genetic models of ASD and Schizophrenia

nature
neuroscience

Article | Published: 12 March 2018

Social deficits in *Shank3*-deficient mouse models of autism are rescued by histone deacetylase (HDAC) inhibition

Luye Qin, Kaijie Ma, Zi-Jun Wang, Zihua Hu, Emmanuel Matas, Jing Wei & Zhen Yan






Image from Yi et al Science 06 May 2016

Mutation of *SHANK3* gene is causally linked to ASD. HDAC & LSD1 inhib rescue the mice phenotype Qin et al Nat Neurosci. 2018. & Zhen Yan Oral Comm SF-2019



LSD1 inhibition also rescues the *Shank3* ASD phenotype

Zhen Yan Oral Comm SFN-2019




Neuron

ARTICLE | ONLINE NOW


Recapitulation and Reversal of Schizophrenia-Related Phenotypes in *Setd1a*-Deficient Mice

Jun Mukai^{7, 8}, Enriko Cannavò⁷, Gregg W. Crabtree⁹, ... Atsushi Takata⁹, Bin Xu⁹, Joseph A. Gogos⁹


Published: October 09, 2019 • DOI: <https://doi.org/10.1016/j.neuron.2019.09.014>



LSD1 inhibition rescues the contralateral axon branching deficits in-vivo in *Setd1a*^{+/-} mice




Rescue of WM performance in *Setd1a*^{+/-} mice treated with ORY-1001



LSD1 inhibition paves the way for personalized medicine in psychiatry

- SETD1A is a key schizophrenia (SCZ) susceptibility gene¹. Mutations in SETD1A increase the risk of SCZ by 35 times, as well as a number of other neurological disorders. SETD1A is part of the Set1/COMPASS complex, mediates mono-, di-, and tri-methylation of the lysine 4 on the histone H3 protein
- In addition to SETD1A, mutations in other subunits of Set1/COMPASS complex have been reported in SCZ and other neuro-developmental disorders
- Mutant mice carrying a heterozygous loss-of-function mutation of the orthologous gene exhibit alterations in axonal branching and cortical synaptic dynamics, accompanied by specific deficits in working memory that recapitulate SCZ-related alterations
- SCZ patients carrying these mutations identified
- Increased interest by FDA and other regulators to explore a personalized medicine approach in these hard to treat populations



Vafidemstat reduces agitation and aggression: REIMAGINE and REIMAGINE-AD Phase IIa trials

Open label trials: **REIMAGINE** (30 patients, PPAS: n=23 : 9 BPD, 6 ASD, 8 ADHD). **REIMAGINE-AD** (12 moderate/severe AD patients, PPAS: n=7)


Primary endpoint: Safety & Tolerability.

Secondary endpoints: Reduction of aggression as measured by validated scale / Other significant measures

REIMAGINE basket trial

Vafidemstat reduces agitation-aggression and improves overall status in BPD patients and also in ADHD and ASD patients after 2 months of treatment


BPD patients



REIMAGINE-AD trial

Vafidemstat reduces agitation-aggression in moderate and severe AD patients after 6 months of treatment

AD patients



Next steps: The company recognizes a significant development potential for vafidemstat in psychiatric indications

❖ A personalized medicine Phase II trial in SetD1a mutant schizophrenic patients under study in collaboration with a Top US Institution

❖ A personalized medicine Phase II trial in Shank3 mutant Phelan McDermid (ASD) patients under study in collaboration with one of the most important Hospitals in Spain

OPTIONS TO ACCELERATED APPROVAL IN GENETICALLY DEFINED SUBPOPULATIONS OF SCZ AND ASD (45.000-60.000 patients in US^{1,2,3})

Precision Medicine Approach

❖ **PORTICO: a Phase IIb in BPD Under Preparation**

- Double blind, randomized, placebo-controlled, 16-week treatment period
- Spain, US and Europe TBD
- N=100
- **Expected FPI: TBD (4Q20-1Q21 examining Covid-19 impact)**
- Expected LPO: TBD

Canonical Clinical Development

PORTICO, a Phase IIb trial with vafidemstat in all-in BPD patients to treat agitation-aggression (80.000-100.000 patients in US^{4,5})

❖ Additional Phase IIb in agitated-aggressive CNS patients under consideration

1. <https://www.cdc.gov/ncbddd/autism/data.html>
2. https://www.pmsf.org/about_pms/
3. Takata et al.. Neuron 82, 773–780, May 21, 2014
4. Samuels J, et al. Br J Psychiatry. 2002;180:536–542.
5. Company real-life assumptions estimates



ORYZON

**IADADEMSTAT a Phase II Clinical Stage Compound
with a broad developability in oncology**

- LSD1 is involved in different cancers and **in cancer stemness**
- **High levels of LSD1 often correlate with more aggressive forms of cancer and/or bad prognosis**
- **Iadademstat** is a small molecule that selectively inhibits LSD1. Positive preclinical *in-vivo* results in different xenograft models. Best in class. Full characterization published in top-ranked journal

ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia

Tamara Maes,^{1,6,*} Cristina Mascaró,¹ Irigo Tirapu,¹ Angels Estiarte,¹ Filippo Ciceri,¹ Serena Lunardi,¹ Nathalie Guibourt,¹ Alvaro Perdonés,¹ Michele M.P. Lufino,¹ Tim C.P. Somerville,² Dan H. Wiseman,² Oihangir Duy,² Ari Melnick,^{2,4} Christophe Willekens,³ Alberto Ortega,¹ Marc Martinelli,¹ Nuria Valls,¹ Guido Kurz,¹ Matthew Fyfe,¹ Julio Cesar Castro-Palmino,¹ and Carlos Buesá¹

¹Oryzon Genomics, S.A. Carrer Sant Ferran 74, 08940 Cornellà de Llobregat, Spain

²Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The University of Manchester, Manchester M20 4BX, UK

³Department of Medicine, Division of Hematology & Medical Oncology, Weill Cornell Medicine, New York, 10065 NY, USA

⁴Department of Pharmacology, Weill Cornell Medicine, New York, 10065 NY, USA


⁵Drug Development Department (DITEP) and Hematology Department, Gustave Roussy, Université Paris-Saclay, 94805 Villejuif, France

⁶Lead Contact


*Correspondence: tmaes@oryzon.com

<https://doi.org/10.1016/j.ccell.2018.02.002>

POTENTIAL ONCOLOGICAL INDICATIONS:

Solid Tumors 

Small Cell Lung Cancer
Prostate cancer
Colorectal cancer
Bladder cancer
Some breast cancers
Merkel Cell Carcinoma

HemONC 

AML
MDS
Myelofibrosis
Non Hodgkin
Lymphoma

Brain/rare Tumors 

Medulloblastoma
Glioblastoma

MoA well-characterized in SCLC, AML and Medulloblastoma


ALICE: An AML trial with LSD1i in Combination with azacitidine in the Elderly

A Phase IIa study to evaluate the safety, tolerability, dose finding and efficacy of iadademstat (ORY-1001) in combination with azacitidine in older patients with AML in first line therapy

- Single arm & open label. Up to 36 patients to be enrolled. **Primary endpoint:** Safety and tolerability of the combo with hypomethylating agent Azacitidine. **Secondary endpoints:** Responses; time to responses; duration of response; and overall survival. Data for first 6 and 12 and 18 enrolled patients reported at EHA-2019, ASH-2019 & EHA-2020


- Robust signals of clinical efficacy, with ORR of 77%, of which 60% are CR/CRi
- Fast clinical responses, with mean time to response of 37 days
- Longest remission to date 488 days, still ongoing
- Iadademstat and azacitidine combination shows a good safety profile
- Following an interruption of two months due to the Covid-19 pandemic, recruitment has now resumed at the expected rate

ORYZON latest Phase II iadademstat efficacy data in AML at EHA-2020



Iadademstat a therapeutic approach for SCLC with a well defined MoA






- LSD1 is a **well characterized target in SCLC**
- LSD1 inhibitors are effective in several in-vitro and in-vivo models of SCLC
- Characterized MoA
- Iadademstat produces **complete and durable tumor regression** in different **chemoresistant PDX models**
- Iadademstat is **efficacious in combos with platinum/etoposide and other agents**
- Identified and patented biomarkers that differentiate tumors by their sensitiveness to LSD1i
- Phase II trial ongoing in second line SCLC patients using these **biomarkers to stratify patients and identify super-responders**



Iadademstat is efficacious in monotherapy in some PDX-SCLC xenografts

Response to iadademstat in PDX models of SCLC is remarkably strong and durable in some cases

- FHSC04 model: derived from a SCLC patient who relapsed after first line therapy
- **6/10 FHSC04 mice treated with iadademstat did not show relapse after 300 days**
- Biomarkers for LSD1 responsiveness identified and used to stratify patients in CLEPSIDRA




Sci Signal. 2019 Feb 5;12(567).

Iadademstat: SCLC - Phase II CLEPSIDRA - preliminary efficacy signals

CLEPSIDRA: A Phase IIa study to assess the safety and efficacy of iadademstat (ORY-1001) in combination with CbEt chemotherapy in 2L-ED SCLC patients who are positive to candidate predictive biomarkers

Preliminary Results



- ❖ **75% clinical benefit rate** (6/8 eval.): **50% OR**: 4 PRs and 2 long-term SD
- ❖ Current level of observed responses suggests that **patient selection by Biomarkers** may be effective to increase ratio of ORs




Patient 1	cycle 1	cycle 2	cycle 3	cycle 4	cycle 5	cycle 6	cycle 7	cycle 8	cycle 9	cycle 10	cycle 11	cycle 12	cycle 13
CbEp	60	60	60	60	60	60	60	60	60	60	60	60	60
iadademstat	60	60	60	60	60	60	60	60	60	60	60	60	60
Best response		PR -43,30%		PR -71,20%		PR -78,70%		PR -86,30%		PR -86,30%		PR -86,30%	

- ❖ Main toxicity observed in the combination with carboplatin-etoposide is hematological
- ❖ **iadademstat alone is safe and shows no hematological, general or neuronal toxicity** in ED-SCLC patients, suggesting potential for monotherapy and other combos
- ❖ iadademstat alone sustains further therapeutic benefit

Covid-19 trial: ESCAPE - vafidemstat to prevent ARDS. Summary

ESCAPE: a Phase II study in adult severe COVID-19 patients to prevent ARDS

- *Multicenter, open label, two arms randomized vafidemstat in combination with best supportive care*
- *Two arms, N=20 each*
- *Primary endpoint: efficacy of vafidemstat, in combination with standard of care to prevent Acute Respiratory Distress Syndrome (ARDS) in adult severely ill patients with CoVID-19*
 - ❖ *Reduction in the incidence of patients (%) requiring mechanical ventilation and referral to ICU from day 1 to day 14*
 - ❖ *Decrease in global mortality and mortality associated to CoVID-19 pneumonia within the period from Day 1 to Day 14*
- *Secondary endpoints*
 - ❖ *Reduction of Systemic and pulmonary inflammatory biomarkers associated to CoVID-19 pneumonia: IL-6, IL1-beta, D-dimer-D, PCR, LDH, Ferritin, Total Lymphocytes*
 - ❖ *Others*
- *Recruiting (FPI in April)*




Anticipating a rich flow of clinical catalysts (non-comprehensive selection)

Iadademstat Phase IIs
in oncology

CLEPSIDRA

ALICE



→ IDEAL / CLEPSIDRA-2

→ ALICE-2

ALICE-1 Final data

ALICE-2 preliminary data



Vafidemstat Phase IIs
in CNS

REIMAGINE-AD

ETHERAL

SATEEN

REIMAGINE-AD
ETHERAL-EU
6m Interim data



→ SCZ / SetD1a

→ ASD / Shank-3


→ PORTICO



Data ASD / Shank-3



Data SCZ / SetD1a



Potential Conferences where data may be presented & potential meetings with regulatory agencies


ORYZON – a unique investment opportunity in an epigenetic platform

- A differentiated proposition in **EPIGENETICS** drugs in **CNS and ONCOLOGY** around one of the most interesting targets in the field: **LSD1**
- **2 molecules** in **Phase II** with promising clinical signals of efficacy in patients
- **Pioneers in CNS epigenetics**
 - ❖ Vafidemstat shows efficacy in agitation in psychiatric disorders (BPD, ADHD, ASD) and in AD
 - ❖ **Phase IIb in Borderline personality disorder in preparation**. Additional trials in agitation in AD, ADHD or ASD under evaluation
 - ❖ Trials in genetically-defined patient subpopulations in SCZ and ASD under study → **Options to get accelerated approval**
- **Most advanced LSD1i (iadademstat) in Oncology**
 - ❖ **Positive preliminary efficacy results** reported in the ongoing Phase II trials in AML and SCLC
 - ❖ **SCLC trial is a biomarker-guided** study to stratify responsive patients
 - ❖ **Options to get accelerated approval**
- **Rich pipeline** of clinical **news** expected in the next quarters. Clinical operations in US started and under expansion
- A **cash efficient** company with a seasoned international management team
- **≈€150M market cap**. One of the most liquid¹ stocks in the microcap group on the Spanish Stock Exchange with **a potential dual listing on Nasdaq in the future**
- Steady **presence in the US market in the last 4 years**. Four successful PIPEs executed in 2017-20 led by US investment Banks and with participation of US-EU-Israeli investors

¹<https://finance.yahoo.com/quote/ORY.MC?p=ORY.MC>

An experienced and committed Management Team

▪ CEO



CARLOS BUESA: CEO & President. Spain/US

PhD in Biochemistry and Molecular Biology. Founder and CEO since inception. Advanced programs on finance, business development, negotiation skills and human resources. He is also PADE at the IESE Business School. He is Board Member of the VC Fund Inveready

▪ CSO



TAMARA MAES: CSO & VicePresident. Spain

PhD in Biotechnology . Founder and Chief Scientific Officer since inception. Responsible for the creation of the whole pipeline of the company and the biological target validation programs. She is SAB member on several public institutions as CSIC and private companies. Since 2016 Scientific Advisor of the ADDF

▪ VP Clinical Development



MICHAEL T. ROPACKI: US

VP of Clinical Development

PhD in Clinical Neuropsychology . Dr. Ropacki has held roles of increasing responsibility for + 10y at Johnson & Johnson, his last as Director of Clinical Development, Neuroscience, Research and Development, for Janssen R&D serving as the Clinical Lead responsible for developing and leading the Cognitive Health in Aging Registry. Prior to that role he served as Global Medical Affairs Leader, Head of Late-Stage Development at Janssen AD Immunotherapy, LLC.

▪ Medical Director



ROGER BULLOCK: UK /PT/Spain

Chief Medical Officer

Graduated in Physiological Sciences at Keble College in Oxford University and got his MB.BS at London University

Extensive experience as clinical researcher, having participated in more than 70 clinical trials in Alzheimer's disease and other CNS conditions

30-year research career, more than 100 peer-reviewed publications and book chapters

He has worked as a consultant for companies active in the CNS space, including Lilly and Merck

▪ Clin Ops Director



SONIA GUTIERREZ: Spain

Chief of Clinical Operations

BSc. Pharm. & MSc. & PDD in IESE Business School. More than 20 years of experience in the clinical research and operations area at different International Pharma & Biotech companies. CNS: +13y in Lundbeck involved in + 40 Clinical Trials in CNS.

Experience in oncology and other indications in Regeneron and other companies.

▪ IP Director



NEUS VIRGILI: Spain

Chief IP Officer

B.Sc. in Organic Chemistry from the University of Barcelona

Qualified European Patent Attorney

She has +20ys experience in pharmaceutical IP

Since 2011 Chief IP Officer at Oryzon

▪ CFO



ENRIC RELLO: Spain

Chief Financial Officer

J.D.; PhD in Economics & Business Administration.

PLD - Program for Leadership Development, Harvard Business School.

BSc & MSc in Business Administrations & Laws, HBS Finance Excell. Prog. Harvard Business School.

From 1997 until 2007 CFO of SANDOZ (NOVARTIS), Spanish Arm.

CFO at Oryzon since 2011

▪ BDO



EMILI TORRELL: Spain

Chief BD Officer

B.Sc. in Sciences, Autonomous University of Barcelona

MBA at ESADE and PDG at IESE Business School

In the business development area from 1990 in the most relevant Spanish companies Prodesfarma, Almirall and Laboratorios Esteve

From 2007 BD Director at Oryzon

▪ VP of Clinical Portfolio



JORDI XAUS: Spain

VP of Clinical Portfolio & Innovation

PhD in Immunology

Former CSO at Palau Pharma

Head of Immunology at Puleva Biotech

Researcher at Genentech

Exec Master in Ops and Innovation by ESADE

- An experienced and respected managerial team in the Biopharmaceutical industry
- Team members have a track record in product discovery & in advancing successfully through product development phases
- Demonstrated ability to close world class deals and to lead and participate in international consortia

ORYZON

Pioneering Personalized Medicine in
EPIGENETICS

